Brief: Elicera Therapeutics Q2 Operating Loss Widens To SEK 4.5 Mln
29/08/2023 07:23
Aug 29 (Reuters) - Elicera Therapeutics AB ELIC.ST :
* Q2 OPERATING LOSS TOTALED SEK -4,466,286 (-3,641,800)
Source text for Eikon: ID:nWkrbjPkg5
Further company coverage: ELIC.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Elicera Therapeutics AB
See all newsBrief: Nomination Committee Proposes Margareth Jorvid As Chair Of Elicera Board
Brief: Elicera Therapeutics Carries Out Rights Issue Of About SEK 73 Mln
Sweden's Elicera Therapeutics Q1 loss narrows, reports positive clinical progress
Brief: Elicera Therapeutics Q1 Operating Loss SEK 5.1 Mln
Brief: Elicera Therapeutics Gets Notice Of Allowance For Japanease Patent